COX-2 Inhibitors

Painkiller blocks unwanted effects of morphine
Wednesday, December 26, 2007

Canada pulls Novartis's drug on hepatitis fears
Thursday, October 04, 2007
Canada said on Thursday it has stopped the sale of Novartis Pharmaceuticals Canada Inc's...

Statins don't curb colon cancer risk: study says
Monday, September 17, 2007
Statin heart drugs do not appear to lower the risk of colorectal cancer, new research shows.

Novartis tells European MDs of Prexige measures
Friday, August 24, 2007
Swiss drugmaker Novartis AG has informed doctors in Europe of new restrictions on prescribing...

Ibuprofen may improve liver-related brain deficits
Wednesday, August 15, 2007
Treatment with the commonly used over-the-counter drug ibuprofen (Motrin, Advil), may reduce the...

Etoricoxib and naproxen effective for arthritis
Monday, July 30, 2007
The COX-2 inhibitor etoricoxib and the older agent naproxen are both safe and effective for the...

Pain drugs have different heart risks
Monday, July 16, 2007
The various anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, which are used to...

Vioxx short-term risk not seen in other data: lawyer
Tuesday, July 03, 2007
A lawyer who represents Merck & Co. in its litigation over Vioxx said on Tuesday that an unpublished...

New COX-2 inhibitor may also lower blood pressure
Friday, June 15, 2007
Lumiracoxib, developed by Novartis AG under the trade name Prexige, is a COX-2 inhibitor analgesic...

Heart experts say Merck arthritis drug too risky
Friday, April 06, 2007
Two prominent U.S. heart experts said studies of Merck & Co. Inc. arthritis drug Arcoxia revealed...

Ibuprofen may affect heart in high-risk patients
Thursday, April 05, 2007
Compared to treatment with the COX-2 inhibitor lumiracoxib (Prexige), ibuprofen appears to increase...

Merck's Vioxx not cause of patient's death - jury
Tuesday, March 27, 2007
EDWARDSVILLE, Illinois (Reuters) - An Illinois jury on Tuesday found Merck & Co. Inc.'s withdrawn...

Merck arthritis drug has fewer side effects
Friday, February 09, 2007
A new arthritis drug made by Merck & Co. causes fewer stomach disorders and complications than an...

COX-2 drugs may raise risk of repeat heart attack
Monday, January 29, 2007
A large study confirms that Vioxx (rofecoxib), but not Celebrex (celecoxib), is associated with...

Merck says Philadelphia Vioxx plaintiff drops suit
Monday, January 22, 2007
Merck & Co. said on Monday a plaintiff, who alleged the drugmaker's Vioxx painkiller caused her...

US panel backs Pfizer drug for juvenile arthritis
Thursday, November 30, 2006
Pfizer Inc.'s pain reliever Celebrex should be approved for treating rheumatoid arthritis in...

U.S. drug reviewers question Pfizer pain drug data
Tuesday, November 28, 2006
U.S. drug reviewers have questioned Pfizer Inc.'s data showing the pain reliever Celebrex is as...

Merck sends heart data on Vioxx successor to FDA
Friday, November 10, 2006
Merck & Co. Inc. on Friday said it sent data on heart risks to U.S. regulators in answer to concerns...

Painkillers associated with birth defects
Monday, August 28, 2006
Women who take common painkillers known as non-steroidal anti-inflammatory drugs (NSAIDS) during the...

Painkillers may pose risk after heart attack
Monday, June 19, 2006
Among people who have survived a heart attack, taking certain types of painkillers is associated...

High doses of common painkillers raise heart risk
Friday, June 02, 2006
High doses of some older, commonly used painkillers, as well as newer drugs known as COX-2...

NSAIDs similar to COX-2 inhibitors in raising risk of atherothrombosis
Thursday, June 01, 2006
High-dose regimens of ibuprofen or diclofenac and use of selective cyclooxygenase-2 (COX-2)...

Large study documents short-term safety of celecoxib for osteoarthritis
Monday, February 27, 2006
The cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) causes fewer gastrointestinal...

COX-2 blockers may curb breast cancer risk
Wednesday, February 15, 2006
The regular use of certain COX-2 inhibitors and other NSAIDs apparently leads to a significant...

Study questions greater GI safety of COX-2 inhibitors
Thursday, December 01, 2005
COX-2 selective inhibitors, such as rofecoxib (Vioxx) or celecoxib (Celebrex), have been billed as...

On February 16, 2005, the Food and Drug Administration began advisory committee meetings on the risks posed by the popular prescription painkillers known as COX-2 inhibitors. Although drugs like Vioxx, Celebrex and Bextra have become household names, new evidence has emerged indicate these drugs can increase the risk of strokes, heart attacks and/or severe coronary episodes by more than 300%.

Even more startling are the questions that have been uncovered: how long have the drug manufacturers known about these fatal side effects? How many patients really needed to take these drugs at all?

As the FDA and the European Medicines Agency begin hearings on just how much of a threat COX-2 inhibitors pose to the general public, other organizations are not waiting for a recall. USA Today reported on how doctors are being urged to not prescribe COX-2 inhibitors to patients because of the risk of developing heart disease. British regulators have advised physicians to switch patients with heart disease to different drugs "as soon as is convenient".

In January 2005, Kaiser Permanente, the nation's largest not-for-profit HMO, ordered its pharmacies to stop dispensing Bextra because of the related heart risks. Such boycott's are now common ground as the number of defective drug reports steadily increase.
"[COX-2 inhibitors] are doomed drugs that are in the twilight of their existence." - Sidney Wolfe, director of advocacy group Public Citizen's Health Research Group

If you or a loved one have taken a COX-2 inhibitor like Vioxx, Celebrex or Bextra and have experienced any side effects, including blood clots, heart attacks, strokes or even sudden death, contact us immediately at 800-966-4999 or fill out the free case evaluation form to the right of your page for an immediate review of your case.

Schwartzapfel Partners

With over 150 years of combined experience and highly competent co-counsel throughout the country, we can serve all your legal needs. Schwartzapfel Partners protects the rights of those who aren't able to do so themselves. Learn More

Gender: Male Female

In what state did the incident occur?

Schwartzapfel Truhowsky Marcus
Sachs P.C. disclaimer.